QIAGEN powered by

Pharmaceutical Development

Whether searching for clinically applicable biomarkers, designing a new companion diagnostic (CDx), or honing your study accrual and go-to-market strategies, we have the pharmaceutical development service offerings to set you on the path to success.

Bring the power of precision medicine to more patients

The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world. 

To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.

From biomarker discovery and validation to trial design and label expansion, QIAGEN Real-World Insights (RWI) helps you bridge the gap between actionable insight and real-world action.

Overcome the inefficiencies of drug development

Drug development is a lengthy, complex, and costly process, entrenched with a high degree of uncertainty that a drug will actually succeed. 

QIAGEN’s Real-World Insights (RWI) portfolio combines robust real-world data from over 200,000 cancer cases and advanced analytics to shorten development timelines, optimize study designs, and improve patient outcomes.

How is RWI driving impact? 

QIAGEN RWI is a professional and personalized service empowering pharmaceutical companies to better understand their target populations. RWI helps you get drugs to market faster, expand their usage to new indications, and confidently answer critical questions, such as:

  • Which biomarkers to target?
  • What variants to include?
  • Which patients to select?

Fireside Chat with Debiopharm: Using QIAGEN real-world genomic data to support drug development

Join us on Tuesday, June 9 at 11 AM ET for a live interactive webcast, where the QIAGEN Real-World Insights team will interview Dr. Anna Pokorska-Bocci, PhD, of Debiopharm International. The conversation will address the challenges of developing oncology targeted therapies and how Debiopharm was able to accelerate drug development with customized analyses and solutions from QIAGEN Real-World Insights. Register here.

RWI applications:

Biomarker and Indication Selection

Choose the best biomarkers and cancer indications for your molecularly targeted therapies

Cohort Stratification and CDx Design

Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success

Molecular Profiling

Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses

Trial Accrual and Drug Market Plans

More easily find the right patients and quickly move to recruitment and regulatory acceptance

Custom RWI Projects

Create and deliver bespoke RWI projects with a range of flexible options and services tailored to your unique requirements

"Understanding how this kind of real-world data (RWD) can add to the body of evidence to inform regulatory decisions continues to be an area of immense interest in the research and medical community, as well as a key strategic priority for the FDA. At the end of the day, care of an individual patient should be informed by reliable evidence derived from studies reflective of their personal and clinical story."

Amy Abernethy, M.D., Ph.D.,
Principal Deputy Commissioner – Food and Drug Administration (FDA)